PregnancyNCT02221895
The Effect of Early Versus Traditional Follow-Up on Breastfeeding Rates at 6 Months
A study testing Postpartum follow up appointment 2-3 weeks after delivery and Postpartum follow up 6-8wk after delivery in people with Pregnancy and Breastfeeding, run by Madigan Army Medical Center at 1 site in United States.
Trial summary
The study's purpose is to determine if early (2-3 week) versus traditional (6-8 week) postpartum follow up is associated with a higher rate of breastfeeding at 6 months. The study's hypothesis is that follow up at 2-3 weeks postpartum is associated with a higher rate of breastfeeding 6 months postpartum. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pregnancy, Breastfeeding, Contraception
- What is being tested?
- Postpartum follow up appointment 2-3 weeks after delivery and Postpartum follow up 6-8wk after delivery
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 344 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2014to May 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18 or above at time of delivery
- Delivery of live born infant at estimated gestational age (EGA) ≥37wk
- Postpartum primiparous patients within the first 48 hours after delivery
- Patient intent to breastfeed
- Breastfeeding initiated within the first 48 hours of delivery and/or prior to hospital discharge (whichever occurs first)
- Infant is continuously rooming in with mother from the time of delivery
Show all 10Show fewer
- English-speaking
- Able to read and complete surveys
- No anticipated discharge from military system, Tricare benefits, or move planned in the upcoming 6 months
- Willing to render informed consent
Who cannot join
- Patients delivered by the Family Medicine Department (relatively small number in our population who are not followed postpartum by the Department of Obstetrics and Gynecology)
- Any condition deemed by patient provider to be an absolute contraindication to breastfeeding
- Maternal HIV/AIDS
- Planned use of radioactive or chemotherapeutic medications or medication for other medical problems which is contraindicated for delivery
- Known fetal factor that would impair breastfeeding
- Fetal mid-facial defects
Show all 10Show fewer
- Known fetal chromosomal abnormality
- Known fetal conditioning resulting in fetal hypotonia
- Labor and Delivery complications
- Maternal separation from infant during the first 48 hours postpartum (such as maternal ICU admission, infant NICU admission)
Trial locations and contacts
1 site in 1 country.
United States1 site
Madigan Army Medical Center
Tacoma, Washington, 98431
About this study
Official title: The Effect of Early (2-3 Week Postpartum) Versus Traditional (6-8 Week Postpartum) Follow-Up on Breastfeeding Rates at 6 Months
The study's purpose is to determine if early (2-3 week) versus traditional (6-8 week) postpartum follow up is associated with a higher rate of breastfeeding at 6 months. The study's hypothesis is that follow up at 2-3 weeks postpartum is associated with a higher rate of breastfeeding 6 months postpartum.
Read the detailed description
This study is a non-blinded randomized controlled trial with intent to treat analysis intended to determine whether early (2-3 weeks postpartum-experimental arm) versus traditional (6-8 weeks postpartum-control arm) follow up increases breastfeeding rates at 6 months' postpartum. For purposes of this study, breastfeeding will be defined as any breast milk produced by the mother and fed to her infant (whether by placing the infant to the breast or pumping/expressing milk and feeding it to the infant in another way). A literature search failed to identify any study that evaluated benefits or shortcomings of an exclusive short interval postpartum visit instead of the 6-8 week traditionally timed visit. Although there may be practical reasons to delay postpartum follow up until 6-8 weeks after delivery, there is no good data to support this, and it may remain the dominant practice due solely to convention. Recent expert opinion has suggested that earlier postpartum follow up may be more practical and provide an earlier or more convenient opportunity to provide assessment and education to postpartum women [9]. Earlier follow up may present a more timely opportunity to discuss family planning, breastfeeding, and screen for depression. Pierce CountyWomen/Infants/Children Program (WIC) data indicates a 34% breastfeeding rate in the military beneficiary population 6 months' postpartum (2012 data). Using a sample size of 166 in the exposure and non-exposure arms would allow for detection of a 50% increase in the outcome of the exposure arm using a two-sided test with α = 0.05 and β = 0.20. A 50% increase in the rate of breastfeeding 6 months' postpartum (from 34% to 51%) would be a clinically significant increase that approximates the Surgeon General's 2020 goal of a 60.6% rate of breastfeeding at 6 months. We assume at 30% dropout rate, and therefore, plan to recruit a total of 346 patients to the study.
Potential enrollees will be evaluated, recruited, and enrolled using the process described in 6.2.3(b). A screening and enrollment log will track all patients reviewed for eligibility whether or not they met inclusion/exclusion criteria and, if so, whether participation in the study was accepted or declined. Patients who agree to enroll will sign the required study consent and complete the breastfeeding attrition prediction tool (BAPT). With the subject's assistance, the enrolling investigator will complete the demographic sheet. Once these items are complete, randomization will occur. Randomization will be via computer-generated block randomization with block sizes of six. Randomization and blocking will be performed using the RAND function in Excel. Randomization will be performed by the study's collaborating staff, who will have no direct contact with the potential subjects. Treatment "A" will represent follow up 2-3 weeks postpartum. Treatment "B" will represent follow up at 6-8 weeks postpartum. The randomized assignments denoted as either "Treatment A: 2-3 week follow up" or "Treatment B: 6-8 week follow up" will be placed on a card within sequentially numbered, sealed, opaque envelopes by the collaborating staff. The randomization process, card, and envelope preparation will all be completed by the collaborating staff without any involvement of the study investigators. These sequentially numbered and sealed envelopes will be secured on Labor and Delivery until the study investigator allocates an envelope to the enrollee. Once a patient agrees to enrollment, the required demographic and screening tools are completed and the study consent form signed, the box containing the sequentially numbered and sealed envelopes will be opened by the study investigator and the patient will be given the next envelope in the sequence. Prior to opening the envelope, the study investigator will denote on the enrollment log the date of subject enrollment and the sequence number of the envelope assigned to the subject. The envelope number assigned to the subject will be their study number. The subject will then open the assigned envelope to determine their treatment assignment, and the study investigator will denote the study arm assignment on the enrollment log.
Once assigned to a treatment arm, the screening and enrollment log designating treatment assignments will be used to coordinate with the clerk in the Ob/Gyn Clinic, who will contact the subject to schedule postpartum follow up at the allotted interval. The scheduled appointments will be with providers (nurse practitioners and nurse midwives) not associated with the study. At the postpartum visit, the subject will complete and return the postpartum questionnaire, along with the Edinburgh perinatal depression screen, which is standard screening completed by all postpartum patients. Subjects demonstrating an elevated depression screen will be followed and assessed according to previously approved departmental protocol (MAMC Perinatal Screening Program Algorithm). Subjects who fail to show up at the assigned follow up interval will be included in the 6-month postpartum assessment. Subjects who return for follow up at intervals outside their assigned appointment interval will also be contacted for the 6- month follow up and included in their originally assigned group for data analysis (intent-to-treat).
When the patient is 5-6 months' postpartum, a study investigator will telephonically contact the subject to obtain answers to the 6-month postpartum questionnaire. The questionnaire will be reviewed by standardized script.
A multitude of factors influence breastfeeding success for mothers choosing to breastfeed. Some of these factors include prior breastfeeding experience, maternal and fetal medical complications, social support, attitudes, education, age, race, and other demographic factors, as well as maternal-fetal proximity within the immediate postpartum period. To minimize potential confounders and bias, we aim to enroll only primiparous mothers, as these mothers are unlikely to have prior breastfeeding experience. Demographic information collected will be used to perform subset analyses and evaluate the homogeneity of the two study groups. The standardized assessment tools will be used to characterize maternal attitudes and support for breastfeeding and will also be used for subset analysis. Some neonates are unable to be with their mother immediately after birth due to a variety of issues that may warrant observation in the Neonatal Intensive Care Unit (NICU) or, in some cases, due to maternal illness. We will also exclude mothers whose infants are not rooming-in with them continuously for the first 48 hours postpartum, as this may pose a potential barrier to initiating breastfeeding. To ensure the study is generalizable, we will include mothers with spontaneous or operative deliveries, as well as cesarean deliveries, which constitute approximately 16% (nulliparous term singleton vertex cesarean birth rate at our facility in 2012) of primiparous births at our facility, as long as the other inclusion/exclusion criteria are met. Additionally, some patients may present for enhanced follow up (in the case of a complicated delivery or postpartum complication) or acute visits within the first 8 weeks' postpartum. These visits represent other opportunities outside the typical postpartum follow up appointment for mothers to seek evaluation for breastfeeding support or other concerns. We will collect data on the number and type of scheduled and unscheduled provider encounters that occur within our medical system outside of the scheduled postpartum follow up appointment. Furthermore, some subjects may fail to follow up at the assigned interval. Data analysis will be via an intent-to-treat, therefore, subjects assigned to one arm or the other who either fail to follow up at the assigned interval or follow up more frequently will still be evaluated and assessed for the primary outcome.
- Describe what will happen on this study that is EXPERIMENTAL: Subjects in the experimental arm (2-3 week postpartum follow up) will have their postpartum appointment at an earlier interval that what is current considered the standard of care. All study participants will complete the BAPT. Demographic data will be obtained for each subject prior to their discharge. All subjects will also complete a standardized postpartum questionnaire at their scheduled postpartum visit (either 2-3 weeks or 6-8 weeks depending on their arm of the study). All subjects will have a 6-month follow up via a standardized/scripted phone survey.
- Describe what will happen on this study that is STANDARD of CARE: The control arm of the trial will be assigned to the traditional 6-8 week postpartum visit. All study subjects will receive postpartum follow up care.
- Conditions
- Pregnancy, Breastfeeding, Contraception, Cervical Cancer, Postpartum Depression
- Being tested
- Postpartum follow up appointment 2-3 weeks after delivery, Postpartum follow up 6-8wk after delivery
- Keywords
- postpartum appointment, breastfeeding, postpartum contraception, postpartum cervical cancer screening, postpartum depression screening
- Medical subject headings
- Breast Feeding, Uterine Cervical Neoplasms, Depression, Postpartum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Postpartum follow up appointment 2-3 weeks after deliveryOther
experimental arm
Postpartum follow up 6-8wk after deliveryOther
control arm
| Study group | Role | What they receive |
|---|---|---|
| Early Follow-up | Experimental | Postpartum follow up appointment 2-3 weeks after delivery Receives: Other: Postpartum follow up appointment 2-3 weeks after delivery |
| Traditional Follow-up | Active comparator | Postpartum follow up 6-8wk after delivery (current clinical standard) Receives: Other: Postpartum follow up 6-8wk after delivery |
What is being measured
The primary outcome is the main question the study is designed to answer.
breastfeeding
Breastfeeding is defined, for purposes of this study, as any breast milk produced by the mother and fed to the infant (by placing the infant to the breast or by pumping or manually expressing and feeding to the infant by other means). Nominal/categorical assessment (breastfeeding to any degree: yes or no) of breastfeeding will be used to determine the primary outcome.
Measured: 5-6 months postpartum
Secondary outcomes (6)
breastfeeding
Subset analysis of primary outcome using additional nominal characterization (breastfeeding only with no other foods/water, breastfeeding with some table foods, breastfeeding and formula feeding with or without some table foods, formula feeding with or without some table foods, formula only).
Measured: 5-6 months postpartum
Contraception
Choice, use, prescription for contraception in the 6 months postpartum period.
Measured: up to 6 months after delivery
Depression screen
Score of Edinburgh depression screen at time of postpartum encounter
Measured: up to 8wk postpartum
Appointment utilization
Total number of appointments in the 8 weeks after delivery
Measured: 8wk postpartum
BAPT
use of the BAPT screening tool to predict breastfeeding attrition
Measured: within 48hr of enrollment
Cervical cancer screening
number of patients who had a pelvic examination at the time of their postpartum appointment
Measured: up to 8wk postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2014 (estimated)
- Study startMar 2014
- Primary completionMay 2017
- Study completionMay 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 344 participants (actual)
Sponsor and investigators
- Lead sponsor
- Madigan Army Medical Center
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Jonathon Abbott, MD, Principal investigator, Madigan Army Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02221895
- Sponsor's protocol ID
- 214030
- Status last verified
- Sep 2020
- First submitted
- 18 Aug 2014
- Last updated
- 21 Sep 2020
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Abbott JL, Carty JR, Hemman E, Batig AL. Effect of Follow-Up Intervals on Breastfeeding Rates 5-6 Months Postpartum: A Randomized Controlled Trial. Breastfeed Med. 2019 Jan/Feb;14(1):22-32. doi: 10.1089/bfm.2018.0071. Epub 2018 Nov 9.
PubMed 30412416
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Early (2-3 Week Postpartum) Versus Traditional (6-8 Week Postpartum) Follow-Up on Breastfeeding Rates at 6 Months
- ClinicalTrials.gov ID
- NCT02221895
- Acronym / sponsor ID
- 214030
- Conditions
- Pregnancy, Breastfeeding, Contraception, Cervical Cancer, Postpartum Depression
- Keywords
- postpartum appointment, breastfeeding, postpartum contraception, postpartum cervical cancer screening, postpartum depression screening
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 344 participants (actual)
- Lead sponsor
- Madigan Army Medical CenterUS federal agency
- Study start
- Mar 2014
- Primary completion
- May 2017 (actual)
- Study completion
- May 2017 (actual)
- First posted
- 21 Aug 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study's purpose is to determine if early (2-3 week) versus traditional (6-8 week) postpartum follow up is associated with a higher rate of breastfeeding at 6 months. The study's hypothesis is that follow up at 2-3 weeks postpartum is associated with a higher rate of breastfeeding 6 months postpartum.
Detailed description
This study is a non-blinded randomized controlled trial with intent to treat analysis intended to determine whether early (2-3 weeks postpartum-experimental arm) versus traditional (6-8 weeks postpartum-control arm) follow up increases breastfeeding rates at 6 months' postpartum. For purposes of this study, breastfeeding will be defined as any breast milk produced by the mother and fed to her infant (whether by placing the infant to the breast or pumping/expressing milk and feeding it to the infant in another way). A literature search failed to identify any study that evaluated benefits or shortcomings of an exclusive short interval postpartum visit instead of the 6-8 week traditionally timed visit. Although there may be practical reasons to delay postpartum follow up until 6-8 weeks after delivery, there is no good data to support this, and it may remain the dominant practice due solely to convention. Recent expert opinion has suggested that earlier postpartum follow up may be more practical and provide an earlier or more convenient opportunity to provide assessment and education to postpartum women [9]. Earlier follow up may present a more timely opportunity to discuss family planning, breastfeeding, and screen for depression. Pierce CountyWomen/Infants/Children Program (WIC) data indicates a 34% breastfeeding rate in the military beneficiary population 6 months' postpartum (2012 data). Using a sample size of 166 in the exposure and non-exposure arms would allow for detection of a 50% increase in the outcome of the exposure arm using a two-sided test with α = 0.05 and β = 0.20. A 50% increase in the rate of breastfeeding 6 months' postpartum (from 34% to 51%) would be a clinically significant increase that approximates the Surgeon General's 2020 goal of a 60.6% rate of breastfeeding at 6 months. We assume at 30% dropout rate, and therefore, plan to recruit a total of 346 patients to the study.
Potential enrollees will be evaluated, recruited, and enrolled using the process described in 6.2.3(b). A screening and enrollment log will track all patients reviewed for eligibility whether or not they met inclusion/exclusion criteria and, if so, whether participation in the study was accepted or declined. Patients who agree to enroll will sign the required study consent and complete the breastfeeding attrition prediction tool (BAPT). With the subject's assistance, the enrolling investigator will complete the demographic sheet. Once these items are complete, randomization will occur. Randomization will be via computer-generated block randomization with block sizes of six. Randomization and blocking will be performed using the RAND function in Excel. Randomization will be performed by the study's collaborating staff, who will have no direct contact with the potential subjects. Treatment "A" will represent follow up 2-3 weeks postpartum. Treatment "B" will represent follow up at 6-8 weeks postpartum. The randomized assignments denoted as either "Treatment A: 2-3 week follow up" or "Treatment B: 6-8 week follow up" will be placed on a card within sequentially numbered, sealed, opaque envelopes by the collaborating staff. The randomization process, card, and envelope preparation will all be completed by the collaborating staff without any involvement of the study investigators. These sequentially numbered and sealed envelopes will be secured on Labor and Delivery until the study investigator allocates an envelope to the enrollee. Once a patient agrees to enrollment, the required demographic and screening tools are completed and the study consent form signed, the box containing the sequentially numbered and sealed envelopes will be opened by the study investigator and the patient will be given the next envelope in the sequence. Prior to opening the envelope, the study investigator will denote on the enrollment log the date of subject enrollment and the sequence number of the envelope assigned to the subject. The envelope number assigned to the subject will be their study number. The subject will then open the assigned envelope to determine their treatment assignment, and the study investigator will denote the study arm assignment on the enrollment log.
Once assigned to a treatment arm, the screening and enrollment log designating treatment assignments will be used to coordinate with the clerk in the Ob/Gyn Clinic, who will contact the subject to schedule postpartum follow up at the allotted interval. The scheduled appointments will be with providers (nurse practitioners and nurse midwives) not associated with the study. At the postpartum visit, the subject will complete and return the postpartum questionnaire, along with the Edinburgh perinatal depression screen, which is standard screening completed by all postpartum patients. Subjects demonstrating an elevated depression screen will be followed and assessed according to previously approved departmental protocol (MAMC Perinatal Screening Program Algorithm). Subjects who fail to show up at the assigned follow up interval will be included in the 6-month postpartum assessment. Subjects who return for follow up at intervals outside their assigned appointment interval will also be contacted for the 6- month follow up and included in their originally assigned group for data analysis (intent-to-treat).
When the patient is 5-6 months' postpartum, a study investigator will telephonically contact the subject to obtain answers to the 6-month postpartum questionnaire. The questionnaire will be reviewed by standardized script.
A multitude of factors influence breastfeeding success for mothers choosing to breastfeed. Some of these factors include prior breastfeeding experience, maternal and fetal medical complications, social support, attitudes, education, age, race, and other demographic factors, as well as maternal-fetal proximity within the immediate postpartum period. To minimize potential confounders and bias, we aim to enroll only primiparous mothers, as these mothers are unlikely to have prior breastfeeding experience. Demographic information collected will be used to perform subset analyses and evaluate the homogeneity of the two study groups. The standardized assessment tools will be used to characterize maternal attitudes and support for breastfeeding and will also be used for subset analysis. Some neonates are unable to be with their mother immediately after birth due to a variety of issues that may warrant observation in the Neonatal Intensive Care Unit (NICU) or, in some cases, due to maternal illness. We will also exclude mothers whose infants are not rooming-in with them continuously for the first 48 hours postpartum, as this may pose a potential barrier to initiating breastfeeding. To ensure the study is generalizable, we will include mothers with spontaneous or operative deliveries, as well as cesarean deliveries, which constitute approximately 16% (nulliparous term singleton vertex cesarean birth rate at our facility in 2012) of primiparous births at our facility, as long as the other inclusion/exclusion criteria are met. Additionally, some patients may present for enhanced follow up (in the case of a complicated delivery or postpartum complication) or acute visits within the first 8 weeks' postpartum. These visits represent other opportunities outside the typical postpartum follow up appointment for mothers to seek evaluation for breastfeeding support or other concerns. We will collect data on the number and type of scheduled and unscheduled provider encounters that occur within our medical system outside of the scheduled postpartum follow up appointment. Furthermore, some subjects may fail to follow up at the assigned interval. Data analysis will be via an intent-to-treat, therefore, subjects assigned to one arm or the other who either fail to follow up at the assigned interval or follow up more frequently will still be evaluated and assessed for the primary outcome.
- Describe what will happen on this study that is EXPERIMENTAL: Subjects in the experimental arm (2-3 week postpartum follow up) will have their postpartum appointment at an earlier interval that what is current considered the standard of care. All study participants will complete the BAPT. Demographic data will be obtained for each subject prior to their discharge. All subjects will also complete a standardized postpartum questionnaire at their scheduled postpartum visit (either 2-3 weeks or 6-8 weeks depending on their arm of the study). All subjects will have a 6-month follow up via a standardized/scripted phone survey.
- Describe what will happen on this study that is STANDARD of CARE: The control arm of the trial will be assigned to the traditional 6-8 week postpartum visit. All study subjects will receive postpartum follow up care.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Early Follow-up | Experimental | Other: Postpartum follow up appointment 2-3 weeks after deliveryPostpartum follow up appointment 2-3 weeks after delivery |
| Traditional Follow-up | Active comparator | Other: Postpartum follow up 6-8wk after deliveryPostpartum follow up 6-8wk after delivery (current clinical standard) |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Age 18 or above at time of delivery
- Delivery of live born infant at estimated gestational age (EGA) ≥37wk
- Postpartum primiparous patients within the first 48 hours after delivery
- Patient intent to breastfeed
- Breastfeeding initiated within the first 48 hours of delivery and/or prior to hospital discharge (whichever occurs first)
Key exclusion criteria (10 listed)
- Patients delivered by the Family Medicine Department (relatively small number in our population who are not followed postpartum by the Department of Obstetrics and Gynecology)
- Any condition deemed by patient provider to be an absolute contraindication to breastfeeding
- Maternal HIV/AIDS
- Planned use of radioactive or chemotherapeutic medications or medication for other medical problems which is contraindicated for delivery
- Known fetal factor that would impair breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Postpartum follow up appointment 2-3 weeks after deliveryexperimental arm | Other | Early Follow-up |
| Postpartum follow up 6-8wk after deliverycontrol arm | Other | Traditional Follow-up |
Primary outcome
breastfeeding
Time frame: 5-6 months postpartum
Breastfeeding is defined, for purposes of this study, as any breast milk produced by the mother and fed to the infant (by placing the infant to the breast or by pumping or manually expressing and feeding to the infant by other means). Nominal/categorical assessment (breastfeeding to any degree: yes or no) of breastfeeding will be used to determine the primary outcome.
6 secondary outcomes
breastfeeding
Time frame: 5-6 months postpartum
Contraception
Time frame: up to 6 months after delivery
Depression screen
Time frame: up to 8wk postpartum
Appointment utilization
Time frame: 8wk postpartum
BAPT
Time frame: within 48hr of enrollment
Cervical cancer screening
Time frame: up to 8wk postpartum
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2020.
- Derived from this study: PubMed 30412416Abbott JL, Carty JR, Hemman E, Batig AL. Effect of Follow-Up Intervals on Breastfeeding Rates 5-6 Months Postpartum: A Randomized Controlled Trial. Breastfeed Med. 2019 Jan/Feb;14(1):22-32. doi: 10.1089/bfm.2018.0071. Epub 2018 Nov 9.
- Individual participant dataSharing planned: Undecided
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonathon Abbott, MD principal investigator
Madigan Army Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Postpartum follow up appointment 2-3 weeks after delivery and Postpartum follow up 6-8wk after delivery in people with Pregnancy and Breastfeeding, run by Madigan Army Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
breastfeeding (time frame: 5-6 months postpartum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02221895, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2020.